Windward Capital Management Co. CA boosted its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 93.4% in the fourth quarter, HoldingsChannel reports. The firm owned 27,501 shares of the biopharmaceutical company’s stock after acquiring an additional 13,281 shares during the period. Windward Capital Management Co. CA’s holdings in Bristol-Myers Squibb were worth $1,685,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in BMY. Patriot Wealth Management Inc. boosted its stake in shares of Bristol-Myers Squibb by 1.5% during the 4th quarter. Patriot Wealth Management Inc. now owns 77,402 shares of the biopharmaceutical company’s stock worth $4,743,000 after buying an additional 1,119 shares during the last quarter. Franklin Street Advisors Inc. NC boosted its stake in shares of Bristol-Myers Squibb by 3.5% during the 4th quarter. Franklin Street Advisors Inc. NC now owns 114,539 shares of the biopharmaceutical company’s stock worth $7,019,000 after buying an additional 3,871 shares during the last quarter. Chesley Taft & Associates LLC boosted its stake in shares of Bristol-Myers Squibb by 3.9% during the 4th quarter. Chesley Taft & Associates LLC now owns 118,075 shares of the biopharmaceutical company’s stock worth $7,236,000 after buying an additional 4,425 shares during the last quarter. Gillespie Robinson & Grimm Inc. boosted its stake in shares of Bristol-Myers Squibb by 26.3% during the 4th quarter. Gillespie Robinson & Grimm Inc. now owns 7,629 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 1,590 shares during the last quarter. Finally, QUANTRES ASSET MANAGEMENT Ltd acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $1,526,000. Hedge funds and other institutional investors own 69.56% of the company’s stock.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now directly owns 584,373 shares in the company, valued at $37,031,717.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Theodore R. Samuels II bought 4,000 shares of the stock in a transaction dated Friday, December 15th. The shares were acquired at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the acquisition, the director now directly owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The disclosure for this purchase can be found here. Company insiders own 0.23% of the company’s stock.

BMY has been the subject of several recent analyst reports. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Citigroup raised their target price on shares of Bristol-Myers Squibb to $72.00 and gave the company a “buy” rating in a research note on Wednesday, October 18th. Vetr downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 target price for the company. in a research note on Tuesday, January 16th. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Monday, December 11th. Finally, Credit Suisse Group set a $62.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, January 22nd. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and an average price target of $65.58.

Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $63.16 on Tuesday. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. The stock has a market cap of $102,621.09, a P/E ratio of 107.05, a price-to-earnings-growth ratio of 1.94 and a beta of 1.09. Bristol-Myers Squibb Co has a 1 year low of $51.56 and a 1 year high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.01. The firm had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 33.68%. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period last year, the business posted $0.63 earnings per share. sell-side analysts anticipate that Bristol-Myers Squibb Co will post 3.22 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were given a dividend of $0.40 per share. The ex-dividend date of this dividend was Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a yield of 2.53%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 271.19%.

TRADEMARK VIOLATION NOTICE: “Windward Capital Management Co. CA Grows Holdings in Bristol-Myers Squibb Co (BMY)” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://theolympiareport.com/2018/02/13/windward-capital-management-co-ca-grows-holdings-in-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.